NCT00613106View on ClinicalTrials.gov

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)

PHASE3CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
OsteoarthritisRheumatoid ArthritisChronic Low Back PainChronic Regional Pain SyndromeChronic Soft Tissue Pain
Interventions
DRUG

HZT-501

Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks

DRUG

Ibuprofen

Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks

Trial Locations (1)

92122

PRA International, San Diego

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY